AstraZeneca Switzerland is pleased to announce that its Country President, Florian Saur, has joined the Board of Interpharma. His election emphasises AstraZeneca's commitment to Switzerland as a pharmaceutical location and its close cooperation with the industry association.
As one of the world's leading companies in pharmaceutical research and development, AstraZeneca is committed to ensuring that all patients have access to innovative therapies as quickly as possible. On the Interpharma Board, Florian Saur aims to make an active contribution to the successful development of a more sustainable and resilient healthcare system. His election is the result of a trusting collaboration with the industry association and he comments as follows:
«When I took over the role of Country President of AstraZeneca Switzerland a year and a half ago, we set ourselves a clear goal: We want to improve the lives of patients in Switzerland with innovative therapies and make a positive contribution to the healthcare system, society and the planet. This can only be achieved with strong partnerships. I look forward to working with Interpharma to further develop one of the best healthcare systems in the world.»
AstraZeneca plans over 35 new therapies between 2025 and 2027
Thanks to investments in research and development, pharmaceutical companies are helping to improve healthcare worldwide. In Switzerland, AstraZeneca focuses on clinical research. The focus here is on investigating medical treatments and therapies for patients in order to test their efficacy and safety as well as the benefits of new medical innovations.
In 2023, AstraZeneca invested around CHF 6 million in clinical research in Switzerland. Between 2025 and 2027, the company plans to make over 35 new therapies available to patients in Switzerland.
Media contact
Tel. +41 (0) 41 725 75 75; media.switzerland@astrazeneca.com
Barbara Hess, Corporate Communications Lead, AstraZeneca Switzerland
AstraZeneca in Switzerland
AstraZeneca is a global, science-led biopharmaceutical company that has been present in Switzerland for nearly 50 years, ranking among the country’s top ten revenue-generating pharmaceutical firms. AstraZeneca focuses on the discovery, development, and commercialisation of prescription medicines in the areas of Oncology, Cardiovascular, Renal and Metabolism, Respiratory and Immunology, and Rare Diseases. Over 285 employees in Switzerland are committed to providing patients with life-changing medicines and making a positive impact on the healthcare system, society, and the planet. Currently, over 230’000 people are treated with a drug from AstraZeneca in Switzerland. Between 2025 and 2027, the company expects the approval of over 35 new therapies. AstraZeneca has pledged to an inclusive work environment based on respect and acceptance. The company was thus recognised as a «Great Place to Work» for the sixth consecutive time in 2024 and carries the «Swiss LGBTI label». AstraZeneca aims to be CO2-negative by 2030.
For more information: www.astrazeneca.ch